Evidence map›Paper›PMID 38609685›Full record

GuidelineIndian journal of pediatrics2024

Management of Intraocular Retinoblastoma: ICMR Consensus Guidelines.

Rachna Meel, Suyash Kulkarni, Lata Singh, Girish Chinnaswamy, Venkatraman Radhakrishnan, Renu Madan, Archana Sasi, Tanvir Kaur, R S Dhaliwal, Sameer Bakhshi

Abstract readPractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Indian journal of pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Retinoblastoma management-Our fight is different!Indian journal of ophthalmology · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Rachna MeelDepartment of Oculoplasty and Ocular Oncology Services, Dr. Rajendra Prasad Centre of Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, 110 029, India. dr.rachnameel@gmail.com.
Suyash KulkarniDepartment of Interventional Radiology, Tata Memorial Hospital, Parel, Mumbai, India.
Lata SinghDepartment of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Girish ChinnaswamyDepartment of Pediatric Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
Venkatraman RadhakrishnanDepartment of Medical Oncology and Pediatric Oncology, Cancer Institute (W.I.A), Adyar, Chennai, India.
Renu MadanDepartment of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Archana SasiDepartment of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
Tanvir KaurDivision of Non-communicable Diseases (NCD Division), Indian Council of Medical Research (ICMR), New Delhi, India.
R S DhaliwalDivision of Non-communicable Diseases (NCD Division), Indian Council of Medical Research (ICMR), New Delhi, India.
Sameer BakhshiDepartment of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India.
All India Institute of Medical Sciences · INIndian Council of Medical Research · INTata Memorial Hospital · INCancer Institute (WIA) · INDR. B.R.A. Institute Rotary Cancer Hospital · INPost Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinoblastoma (RB) is the most common childhood intraocular malignancy. Delayed presentation due to a lack of awareness and advanced intraocular tumors are a common scenario in low-middle income countries (LMICs). Remarkable treatment advances have been made in the past few decades allowing globe salvage in advanced intraocular RB (IORB) including systemic chemotherapy with focal consolidation and targeted treatments like intraarterial chemotherapy and intravitreal chemotherapy. However, a lack of availability and affordability limits the use of such advances in LMICs. External beam radiotherapy, despite risk of second cancers in RB with germline mutations, still remains useful for recalcitrant RB not responding to any other treatment. When choosing conservative treatment for advanced IORB, the cost and long duration of treatment, morbidity from multiple evaluation under anesthesias (EUAs), side effects of treatment and risk of treatment failure need to be taken into account and discussed with the parents. In this article, the authors discuss the ICMR consensus guidelines on the management of IORB.

Indexed as

Retinal NeoplasmsRetinoblastomaConsensusHumansClassificationConsensusGuidelineIntra-arterial chemotherapyIntraocular retinoblastomaIntravenous chemotherapyIntra-vitreal chemotherapy

Identifiers

PMID38609685
OpenAlexW4394769014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.